Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02673151 · ClinicalTrials.gov registry record · Phase 2
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
A Phase 2 study, sponsored by Andrei Iagaru.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT02673151 is a Phase 2 study that has completed, run by Andrei Iagaru. The registered enrollment target is 61 participants.
The verdict
NCT02673151, a Phase 2 study, has completed, sponsored by Andrei Iagaru.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this research study is to see if recurrent prostate cancer can be identified using a special procedure called a positron emission tomography (PET) scan. PET/CT is used to describe information regarding the function, as well as location and size of a tumor.
Interventions
- DRUG 68Ga-PSMA-11
- PROCEDURE Positron Emission Tomography (PET)
- PROCEDURE Computed Tomography (CT) scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2017-05-20 |
| Est. Completion | 2019-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02673151
The ClinicalTrials.gov registry entry for NCT02673151 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrei Iagaru, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 68Ga-PSMA-11 is the first listed.
NCT02673151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02673151 about?
NCT02673151 is a clinical study titled "68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment". The purpose of this research study is to see if recurrent prostate cancer can be identified using a special procedure called a positron emission tomography (PET) scan. PET/CT is used to describe information regarding the function, as well as location and size of a tumor.
What is the current status of trial NCT02673151?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2017-05-20. Estimated completion is 2019-04-27.
What interventions are being tested in trial NCT02673151?
The interventions under investigation include: 68Ga-PSMA-11 (DRUG), Positron Emission Tomography (PET) (PROCEDURE), Computed Tomography (CT) scan (PROCEDURE).
Who is sponsoring clinical trial NCT02673151?
This trial is sponsored by Andrei Iagaru, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.